Regenerative Medicine Market

Regenerative Medicine Market Size, Share & Trends by Product (Stem Cell [Autologous, Allogenic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, Wound care, Cardiovascular Diseases, Eye Disorders) & Region - Global Forecast to 2028

Report Code: BT 4419 Jan, 2024, by marketsandmarkets.com

Regenerative Medicine Market Size, Share & Trends

The size of global regenerative medicine market in terms of revenue was estimated to be worth $16.0 Billion in 2023 and is poised to reach $49.0 Billion by 2028, growing at a CAGR of 25.1% from 2023 to 2028. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.

This is mainly due to various factors such as rising emphasis on personalized medicine, rising partnerships and collaborations by major market players, increased therapeutic area scope and rise in regenerative medicine regulatory approvals. However, the legal and ethical concrns associated with regenerative medicine along with the growing high treatment cost are predicted to cause market growth barriers.

Regenerative Medicine Market Size, Dynamics & Ecosystem

Regenerative Medicine Market Size, Dynamics & Ecosystem

To know about the assumptions considered for the study, Request for Free Sample Report

Global Regenerative medicine Market Dynamics

Driver: Focus on Personalized Medicine

The global market is expected to benefit from the focus on personalized medicines. Precision medicine is an approach to medical treatment that tailors therapeutics, and interventions for individual patients or a subpopulation based on their unique genetic, environmental, and lifestyle characteristics. In 2022, the FDA approved 12 personalized medications, representing approximately 34% of all newly approved therapeutic molecular entities. Personalized treatments account for at least a quarter of new drug approvals since 2015. Moreover, five new gene or cell-based therapies were approved in 2022. These include treatment of rare genetic disorders with few other treatment options – beta thalassemia, hemophilia B, and cerebral adrenoleukodystrophy, refractory multiple myeloma, and certain types of non-muscle invasive bladder cancer.

Restraint: Ethical and Legal concerns and high cost of regenerative medicines

Several ethical issues are associated with the use of stem cells, as these cells are derived by destroying the human embryo. The human embryo is viewed as a potential life, and destroying it is considered unethical even if it can save a human life. Such concerns related to embryonic stem cells for developing stem cell therapy are factors restraining market growth globally. Furthermore, the adoption of stem cells in Middle Eastern countries raises ethical considerations rooted in cultural, religious, and social perspectives. Religious beliefs, particularly in Islam, may influence opinions on the use of embryonic stem cells, posing a challenge as it involves the destruction of embryos. Additionally, due to budget constraints, various research institutes and small-scale companies find it difficult to afford expensive products. In emerging economies, underdeveloped infrastructure facilities and low healthcare expenditure restrict the use of advanced equipment.

Opportunity: Harnessing the Potential of 3D Printing

Technological advancements play a pivotal role in propelling the growth of the tissue engineering market, fostering innovation and expanding the scope of applications within the field. The continual evolution of materials science, bioengineering techniques, and imaging technologies has enabled researchers and engineers to develop sophisticated tissue-engineered products with enhanced functionalities. 3D bioprinting is used for the development of biostructure for orthopedic tissues, bones, and associated organs. In 3D bioprinting, a small unit of living cells, biomaterials, and biochemicals are positioned with the functional components to form tissue like 3D structures. The 3D bioprinting technology offers various advantages, including accurate cell distribution, scalability, high-resolution cell deposition, and cost-effectiveness.

Challenge: Lack of favorable reimbursement policies across various regions

The global market faces a significant hurdle in its growth trajectory due to inadequate or lack of reimbursement policies. The absence of clear reimbursement frameworks for regenerative therapies poses a challenge for both healthcare providers and patients. The inconsistent and complex nature of reimbursement policies across various regions hampers the widespread adoption of these innovative treatments. This factor is likely to restrain the growth of the market.

Regenerative Medicine Market Segmentation & Geographical Spread

Regenerative Medicine Market Segmentation & Geographical Spread

To know about the assumptions considered for the study, download the pdf brochure

The cell therapy segment of regenerative medicine industry commanded market share in 2022.

On the basis of product, the regenerative medicine market is segmented into gene therapy, cell therapy (stem cell therapy [cell transplantations, stem cell therapy products {autologous therapy, allogenic therapy] cell-based immunotherapy products), and tissue engineering products. The cell therapy segment dominated the market in 2022. The rising cell therapy production facilities GMP certification approvals is one of the many factors driving the growth of this segment.

Muskuloskeletal disorders segment of the regenerative medicine industry is likely to grow at significant CAGR during the forecast period.

Based on therapeutic area, the regenerative medicine market is classified into ophthalmology, oncology, neurology, musculoskeletal disorders, cardiovascular diseases, dermatology & wound care and other applications. In 2022, the musculoskeletal disorders segment captured the highest share of the global market due to the increasing prevalence of orthopedic disorders and rise in musculoskeletal regeneration research.

Asia Pacific region of the regenerative medicine industry is predicted to exhibit highest CAGR during the forecast period of 2023-2028.

There are six main regional segmentations for the regenerative medicine market—North America, Europe, the Asia Pacific, Latin America, Middle East and Africa. In 2022, North America dominated the global market with the highest market share. Rising investments in tissue engineering, stem cell banking, and drug discovery, coupled with an expanding healthcare sector and high adoption of cell immunotherapies for cancer and chronic diseases and stem cell therapy, are driving the North American market's robust growth. Additionally, Asia Pacific exhibited the highest CAGR which can be attributed to the rising new technologies demand, increasing per capita income and increasing burden of chronic diseases.

Key players in the regenerative medicine market include Novartis AG (Switzerland), Biogen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen Inc. (US), Smith+Nephew (UK), MEDIPOST Co., Ltd. (Korea), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), and CORESTEM, Inc (South Korea).

Scope of the Regenerative Medicine Industry

Report Metric

Details

Market Revenue Size in 2023

$16.0 Billion

Projected Revenue Size by 2028

$49.0 Billion

Industry Growth Rate

Poised to Grow at a CAGR of 25.1%

Market Driver

Focus on Personalized Medicine

Market Opportunity

Harnessing the Potential of 3D Printing

This report categorizes the regenerative medicine market to forecast revenue and analyze trends in each of the following submarkets:

By Product
  • Cell therapy
  • Stem cell therapy
    • Cell transplantations
    • Stem cell therapy products
      • Autologous therapy
      • Allogenic therapy
  • Cell-based immunotherapy products
  • Gene therapy
  • Tissue engineering
By Therapeutic Area
  • Oncology
  • Musculoskeletal disorders
  • Dermatology & wound care
  • Cardiovascular diseases
  • Ophthalmology
  • Neurology
  • Other applications
By Region
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East
  • Africa

Recent Developments of Regenerative Medicine Industry:

  • In December 2023, the U.S. FDA greenlit a historic treatment, Casgevy (CRISPR Therapeutics.). This first-ever cell-based gene therapy tackled sickle cell disease in patients 12+ and marked a revolutionary step in gene therapy with its novel genome editing tech.
  • In January 2023, Sarepta and Catalent entered into a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001) (ELEVIDYS), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne Muscular Dystrophy (DMD).
  • In August 2023, Gilead Sciences and Tentarix Biotherapeutics entered into three multi-year collaborations to leverage Tentarix's Tentacles platform for the discovery and development of innovative, multi-functional protein-based therapies for cancer and inflammatory diseases.
  • In December 2023, Bristol-Myers Squibb received approval for ABECMA for patients with relapsed or refractory multiple myeloma with at least two prior treatments, including specific medications in Japan.

Frequently Asked Questions (FAQs):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 35)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
           1.3.3 CURRENCY CONSIDERED
    1.4 RESEARCH LIMITATIONS 
    1.5 STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
    1.7 IMPACT OF RECESSION ON REGENERATIVE MEDICINE MARKET 
 
2 RESEARCH METHODOLOGY (Page No. - 40)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 BREAKDOWN OF PRIMARIES: MARKET
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 3 MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS: MARKET, 2022
          FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022
          FIGURE 5 NOVARTIS AG: REVENUE SHARE ANALYSIS, 2022
          FIGURE 6 PRODUCT-BASED REVENUE ANALYSIS, 2022
           2.2.1 PRIMARY INSIGHTS
                    FIGURE 7 VALIDATION FROM PRIMARY EXPERTS
           2.2.2 SEGMENT ASSESSMENT METHODOLOGY: REGENERATIVE MEDICINE INDUSTRY
                    FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
                    FIGURE 9 CAGR PROJECTIONS: MARKET
                    FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES IN REGENERATIVE MEDICINE INDUSTRY
    2.3 MARKET BREAKDOWN & DATA TRIANGULATION 
          FIGURE 11 DATA TRIANGULATION METHODOLOGY
    2.4 STUDY ASSUMPTIONS 
    2.5 RISK ANALYSIS 
    2.6 IMPACT OF RECESSION ON MARKET 
          TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 54)
    FIGURE 12 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 REGENERATIVE MEDICINE INDUSTRY, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 GEOGRAPHICAL SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 57)
    4.1 REGENERATIVE MEDICINE MARKET OVERVIEW 
          FIGURE 15 FOCUS ON PERSONALISED MEDICINE TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: REGENERATIVE MEDICINE INDUSTRY
          FIGURE 16 CELL THERAPY TO COMMAND LARGEST SHARE OF NORTH AMERICAN MARKET
    4.3 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 60)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 18 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growing focus on personalized medicine
                                FIGURE 19 PERCENTAGE OF FDA APPROVALS FOR PERSONALIZED MEDICINE PRODUCTS (2018–2022)
                    5.2.1.2 Emerging applications in new therapeutic areas
                                TABLE 4 REGENERATIVE MEDICINE INDUSTRY: EMERGING APPLICATIONS
                    5.2.1.3 Increasing collaborations and partnerships by major market players
                    5.2.1.4 Increasing regulatory approvals in regenerative medicine
                                TABLE 5 LIST OF KEY PRODUCT APPROVALS IN MARKET, 2021–2023
           5.2.2 RESTRAINTS
                    5.2.2.1 Lack of long-term data
                    5.2.2.2 Ethical and legal concerns and high cost of treatments
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Harnessing the potential of 3D printing
                    5.2.3.2 Integration with artificial intelligence and big data
                    5.2.3.3 Growing number of organ transplants
           5.2.4 CHALLENGES
                    5.2.4.1 Lack of favorable reimbursement policies across various regions
    5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 20 REVENUE SHIFT TOWARD REGENERATIVE MEDICINE COMPANIES
    5.4 PRICING ANALYSIS 
           5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
                    TABLE 6 REGENERATIVE MEDICINE PRICE TREND
    5.5 SUPPLY CHAIN ANALYSIS 
          FIGURE 21 SUPPLY CHAIN ANALYSIS: MARKET
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 22 VALUE CHAIN ANALYSIS: REGENERATIVE MEDICINE INDUSTRY
    5.7 ECOSYSTEM ANALYSIS 
          FIGURE 23 MARKET: ECOSYSTEM ANALYSIS
          TABLE 7 ROLE IN ECOSYSTEM
    5.8 TECHNOLOGY ANALYSIS 
          FIGURE 24 KEY STEPS IN GENE THERAPY
          TABLE 8 STEM CELL THERAPIES AND GENE THERAPIES
    5.9 PATENT ANALYSIS 
          TABLE 9 MARKET: INDICATIVE LIST OF PATENTS
    5.10 KEY CONFERENCES & EVENTS IN 2024–2025 
           5.10.1 REGENERATIVE MEDICINE CONFERENCES IN 2024–2025
                     TABLE 10 REGENERATIVE MEDICINE CONFERENCES IN 2024–2025
    5.11 TARIFF & REGULATORY LANDSCAPE 
           5.11.1 FDA APPROVALS
           5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.12 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 15 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.12.1 THREAT OF NEW ENTRANTS
           5.12.2 THREAT OF SUBSTITUTES
           5.12.3 BARGAINING POWER OF BUYERS
           5.12.4 BARGAINING POWER OF SUPPLIERS
           5.12.5 DEGREE OF COMPETITION
    5.13 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF REGENERATIVE MEDICINE PRODUCTS
           5.13.2 BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS
                     FIGURE 26 KEY BUYING CRITERIA FOR END USERS
    5.14 PIPELINE ANALYSIS 
           TABLE 16 GENE THERAPY PRODUCTS UNDER CLINICAL TRIAL
           TABLE 17 CELL THERAPY PRODUCTS UNDER CLINICAL TRIAL
 
6 REGENERATIVE MEDICINE MARKET, BY PRODUCT (Page No. - 94)
    6.1 INTRODUCTION 
          TABLE 18 REGENERATIVE MEDICINE INDUSTRY, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 CELL THERAPY 
          TABLE 19 MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 20 MARKET FOR CELL THERAPY, BY REGION, 2021–2028 (USD MILLION)
          TABLE 21 NORTH AMERICA: MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 22 EUROPE: MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 23 ASIA PACIFIC: MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 24 LATIN AMERICA: MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.1 STEM CELL THERAPY
                    TABLE 25 MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 26 MARKET FOR STEM CELL THERAPY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 27 NORTH AMERICA: MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 28 EUROPE: MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 29 ASIA PACIFIC: MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 30 LATIN AMERICA: MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.2.1.1 Cell transplantations
                               6.2.1.1.1 Potential of Allo-SCT in treating AML to drive segmental growth
                                              TABLE 31 MARKET FOR CELL TRANSPLANTATIONS, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 32 NORTH AMERICA: MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 33 EUROPE: MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 34 ASIA PACIFIC: MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 35 LATIN AMERICA: MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.2.1.2 Stem cell therapy products
                                TABLE 36 MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 37 MARKET FOR STEM CELL THERAPY PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 38 NORTH AMERICA: MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 39 EUROPE: MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 40 ASIA PACIFIC: MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 41 LATIN AMERICA: MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
                               6.2.1.2.1 Autologous therapy
                                             6.2.1.2.1.1 Low risk of post-treatment complications to support segment growth
                                                               TABLE 42 MARKET FOR AUTOLOGOUS THERAPY, BY REGION, 2021–2028 (USD MILLION)
                                                               TABLE 43 NORTH AMERICA: MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                                               TABLE 44 EUROPE: MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                                               TABLE 45 ASIA PACIFIC: MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                                               TABLE 46 LATIN AMERICA: MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                               6.2.1.2.2 Allogeneic therapy
                                             6.2.1.2.2.1 High potential in disease treatment to ensure demand and development
                                                               TABLE 47 MARKET FOR ALLOGENEIC THERAPY, BY REGION, 2021–2028 (USD MILLION)
                                                               TABLE 48 NORTH AMERICA: MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                                               TABLE 49 EUROPE: MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                                               TABLE 50 ASIA PACIFIC: MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                                               TABLE 51 LATIN AMERICA: MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.2 CELL-BASED IMMUNOTHERAPY
                    6.2.2.1 Growing adoption of T-cell therapy in cancer treatment to support market growth
                                TABLE 52 MARKET FOR CELL-BASED IMMUNOTHERAPY, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 53 NORTH AMERICA: MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 54 EUROPE: MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 55 ASIA PACIFIC: MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 56 LATIN AMERICA: MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 GENE THERAPY 
           6.3.1 STRONG PRODUCT PIPELINE DUE TO BROADENING APPLICATIONS IN DISEASE TREATMENT TO DRIVE MARKET
                    TABLE 57 APPROVED GENE THERAPIES, 2022
                    TABLE 58 MARKET FOR GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 59 NORTH AMERICA: MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 60 EUROPE: MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 61 ASIA PACIFIC: MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 62 LATIN AMERICA: MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 TISSUE ENGINEERING 
           6.4.1 HIGH DEMAND FOR TISSUE ENGINEERING PRODUCTS IN DERMATOLOGY & WOUND CARE APPLICATIONS TO DRIVE MARKET
                    TABLE 63 MARKET FOR TISSUE ENGINEERING, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 64 NORTH AMERICA: MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 65 EUROPE: MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 66 ASIA PACIFIC: MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 67 LATIN AMERICA: MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA (Page No. - 123)
    7.1 INTRODUCTION 
          TABLE 68 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE PRODUCTS, BY THERAPEUTIC AREA, 2021 VS. 2022
          TABLE 69 REGENERATIVE MEDICINE INDUSTRY, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
    7.2 ONCOLOGY 
           7.2.1 INCREASING STEM CELL TRANSPLANTS TO DRIVE MARKET
                    TABLE 70 INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR ONCOLOGY APPLICATIONS
                    TABLE 71 MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 72 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 73 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 74 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 75 LATIN AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 MUSCULOSKELETAL DISORDERS 
           7.3.1 RISING RESEARCH ON MUSCULOSKELETAL REGENERATION AND PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE MARKET
                    TABLE 76 MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 77 NORTH AMERICA: MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 78 EUROPE: MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 79 ASIA PACIFIC: MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 80 LATIN AMERICA: MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 DERMATOLOGY & WOUND CARE 
           7.4.1 RISING USE OF WOUND CARE BIOLOGICS TO DRIVE MARKET
                    TABLE 81 INDICATIVE LIST OF REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR TREATMENT OF ACUTE & CHRONIC WOUNDS
                    TABLE 82 MARKET FOR DERMATOLOGY & WOUND CARE, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 83 NORTH AMERICA: MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 84 EUROPE: MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 85 ASIA PACIFIC: MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 86 LATIN AMERICA: MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)
    7.5 CARDIOVASCULAR DISEASES 
           7.5.1 INCREASING USE OF MSCS FOR CLINICAL RESEARCH ON IHD TO SUPPORT MARKET GROWTH
                    TABLE 87 MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 88 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 89 EUROPE: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 90 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 91 LATIN AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
    7.6 OPHTHALMOLOGY 
           7.6.1 REGENERATION OF EYE TISSUES FOR AMD TO SUPPORT MARKET GROWTH
                    TABLE 92 LIST OF PIPELINE PRODUCTS FOR REGENERATIVE MEDICINE IN OPHTHALMOLOGY
                    TABLE 93 MARKET FOR OPHTHALMOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 94 NORTH AMERICA: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 95 EUROPE: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 96 ASIA PACIFIC: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 97 LATIN AMERICA: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.7 NEUROLOGY 
           7.7.1 GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH
                    TABLE 98 MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 99 NORTH AMERICA: MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 100 EUROPE: MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 101 ASIA PACIFIC: MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 102 LATIN AMERICA: MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.8 OTHER THERAPEUTIC AREAS 
          TABLE 103 MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 104 NORTH AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 105 EUROPE: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 106 ASIA PACIFIC: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 107 LATIN AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 REGENERATIVE MEDICINE MARKET, BY REGION (Page No. - 150)
    8.1 INTRODUCTION 
          FIGURE 27 NUMBER OF PLAYERS IN REGENERATIVE MEDICINE INDUSTRY, BY REGION, 2020–2022
          TABLE 108 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE (2022)
          TABLE 109 REGENERATIVE MEDICINE INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
    8.2 NORTH AMERICA 
          FIGURE 28 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT
          TABLE 110 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 111 NORTH AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
          TABLE 112 NORTH AMERICA: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 113 NORTH AMERICA: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 114 NORTH AMERICA: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 115 NORTH AMERICA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.2.1 US
                    8.2.1.1 Rising number of pipeline products for regenerative medicine to drive market
                                TABLE 116 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 117 US: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 118 US: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 119 US: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 120 US: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.2.2 CANADA
                    8.2.2.1 Rising government initiatives for regenerative medicine research to drive market
                                TABLE 121 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 122 CANADA: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 123 CANADA: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 124 CANADA: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 125 CANADA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.2.3 NORTH AMERICA: RECESSION IMPACT
    8.3 EUROPE 
          TABLE 126 EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 127 EUROPE: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
          TABLE 128 EUROPE: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 129 EUROPE: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 130 EUROPE: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 131 EUROPE: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.3.1 GERMANY
                    8.3.1.1 Rising focus on clinical research and patent approvals to drive market
                                TABLE 132 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 133 GERMANY: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 134 GERMANY: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 135 GERMANY: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 136 GERMANY: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.3.2 UK
                    8.3.2.1 Incorporating regenerative medicine into commercial healthcare services under NHS to drive market
                                TABLE 137 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 138 UK: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 139 UK: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 140 UK: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 141 UK: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.3.3 FRANCE
                    8.3.3.1 Structured regulatory framework to drive regenerative medicine product pipeline
                                TABLE 142 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 143 FRANCE: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 144 FRANCE: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 145 FRANCE: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 146 FRANCE: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.3.4 ITALY
                    8.3.4.1 Rising prevalence of neurological and cardiovascular disorders to drive market
                                TABLE 147 ITALY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 148 ITALY: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 149 ITALY: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 150 ITALY: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 151 ITALY: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.3.5 SPAIN
                    8.3.5.1 Favorable regulatory environment to drive product pipeline
                                TABLE 152 SPAIN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 153 SPAIN: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 154 SPAIN: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 155 SPAIN: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 156 SPAIN: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.3.6 REST OF EUROPE
                    TABLE 157 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                    TABLE 158 REST OF EUROPE: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 159 REST OF EUROPE: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 160 REST OF EUROPE: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 161 REST OF EUROPE: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.3.7 EUROPE: RECESSION IMPACT
    8.4 ASIA PACIFIC 
          FIGURE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT
          TABLE 162 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 163 ASIA PACIFIC: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
          TABLE 164 ASIA PACIFIC: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 165 ASIA PACIFIC: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 166 ASIA PACIFIC: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 167 ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.4.1 CHINA
                    8.4.1.1 Favorable government support for development of regenerative medicine to drive market
                                TABLE 168 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 169 CHINA: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 170 CHINA: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 171 CHINA: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 172 CHINA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.4.2 JAPAN
                    8.4.2.1 Regulatory amendments to pharmaceutical legislation to drive commercialization of therapies
                                TABLE 173 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 174 JAPAN: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 175 JAPAN: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 176 JAPAN: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 177 JAPAN: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.4.3 INDIA
                    8.4.3.1 Introduction of novel therapies for CVD and cancer to support market growth
                                TABLE 178 INDIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 179 INDIA: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 180 INDIA: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 181 INDIA: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 182 INDIA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.4.4 SOUTH KOREA
                    8.4.4.1 Strong research base and availability of funds to support market growth
                                TABLE 183 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 184 SOUTH KOREA: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 185 SOUTH KOREA: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 186 SOUTH KOREA: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 187 SOUTH KOREA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.4.5 AUSTRALIA
                    8.4.5.1 Increasing incidence of sports injuries to support market growth
                                TABLE 188 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 189 AUSTRALIA: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 190 AUSTRALIA: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 191 AUSTRALIA: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 192 AUSTRALIA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.4.6 REST OF ASIA PACIFIC
                    TABLE 193 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                    TABLE 194 REST OF ASIA PACIFIC: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 195 REST OF ASIA PACIFIC: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 196 REST OF ASIA PACIFIC: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 197 REST OF ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.4.7 ASIA PACIFIC: RECESSION IMPACT
    8.5 LATIN AMERICA 
          TABLE 198 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 199 LATIN AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
          TABLE 200 LATIN AMERICA: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 201 LATIN AMERICA: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 202 LATIN AMERICA: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 203 LATIN AMERICA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.5.1 BRAZIL
                    8.5.1.1 Gradual increase in pharmaceutical R&D to support market growth
                                TABLE 204 BRAZIL: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 205 BRAZIL: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 206 BRAZIL: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 207 BRAZIL: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 208 BRAZIL: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.5.2 REST OF LATIN AMERICA
                    TABLE 209 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                    TABLE 210 REST OF LATIN AMERICA: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 211 REST OF LATIN AMERICA: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 212 REST OF LATIN AMERICA: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 213 REST OF LATIN AMERICA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.5.3 LATIN AMERICA: RECESSION IMPACT
    8.6 MIDDLE EAST 
           8.6.1 GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE MARKET GROWTH IN COMING YEARS
                    TABLE 214 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                    TABLE 215 MIDDLE EAST: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 216 MIDDLE EAST: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 217 MIDDLE EAST: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 218 MIDDLE EAST: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.6.2 MIDDLE EAST: RECESSION IMPACT
    8.7 AFRICA 
           8.7.1 GROWING COLLABORATIONS TO SUPPORT GROWTH IN COMING YEARS
                    TABLE 219 AFRICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                    TABLE 220 AFRICA: MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 221 AFRICA: MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 222 AFRICA: MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 223 AFRICA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
           8.7.2 AFRICA: RECESSION IMPACT
 
9 COMPETITIVE LANDSCAPE (Page No. - 216)
    9.1 INTRODUCTION 
    9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 
          TABLE 224 REGENERATIVE MEDICINE MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
    9.3 REVENUE SHARE ANALYSIS 
          FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS (2020–2022)
    9.4 MARKET SHARE ANALYSIS 
          FIGURE 31 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
          TABLE 225 REGENERATIVE MEDICINE INDUSTRY: DEGREE OF COMPETITION
    9.5 COMPANY EVALUATION MATRIX 
           9.5.1 STARS
           9.5.2 EMERGING LEADERS
           9.5.3 PERVASIVE PLAYERS
           9.5.4 PARTICIPANTS
                    FIGURE 32 REGENERATIVE MEDICINE INDUSTRY: COMPANY EVALUATION MATRIX, 2022
           9.5.5 COMPANY FOOTPRINT ANALYSIS
                    TABLE 226 REGENERATIVE MEDICINE INDUSTRY: PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS
                    TABLE 227 REGENERATIVE MEDICINE INDUSTRY: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
    9.6 START-UP/SME EVALUATION MATRIX 
           9.6.1 PROGRESSIVE COMPANIES
           9.6.2 RESPONSIVE COMPANIES
           9.6.3 DYNAMIC COMPANIES
           9.6.4 STARTING BLOCKS
                    FIGURE 33 REGENERATIVE MEDICINE INDUSTRY: START-UP/SME EVALUATION MATRIX, 2022
           9.6.5 COMPETITIVE BENCHMARKING
                    TABLE 228 REGENERATIVE MEDICINE INDUSTRY: DETAILED LIST OF KEY START-UP/SME PLAYERS
                    TABLE 229 REGENERATIVE MEDICINE INDUSTRY: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
    9.7 COMPETITIVE SCENARIO & TRENDS 
           9.7.1 PRODUCT LAUNCHES
                    TABLE 230 REGENERATIVE MEDICINE INDUSTRY: PRODUCT APPROVALS/LAUNCHES, JANUARY 2020 TO DECEMBER 2023
           9.7.2 DEALS
                    TABLE 231 REGENERATIVE MEDICINE INDUSTRY: DEALS, JANUARY 2020 TO DECEMBER 2023
           9.7.3 OTHER DEVELOPMENTS
                    TABLE 232 REGENERATIVE MEDICINE MARKET: OTHER DEVELOPMENTS, JANUARY 2020 TO DECEMBER 2023
 
10 COMPANY PROFILES (Page No. - 239)
     10.1 KEY MARKET PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             10.1.1 NOVARTIS AG
                        TABLE 233 NOVARTIS AG: COMPANY OVERVIEW
                        FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT (2022)
             10.1.2 BIOGEN INC.
                        TABLE 234 BIOGEN INC.: COMPANY OVERVIEW
                        FIGURE 35 BIOGEN INC.: COMPANY SNAPSHOT (2022)
             10.1.3 GILEAD SCIENCES, INC.
                        TABLE 235 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
                        FIGURE 36 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)
             10.1.4 SAREPTA THERAPEUTICS, INC.
                        TABLE 236 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
                        FIGURE 37 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022)
             10.1.5 AMGEN, INC.
                        TABLE 237 AMGEN, INC.: COMPANY OVERVIEW
                        FIGURE 38 AMGEN, INC.: COMPANY SNAPSHOT (2022)
             10.1.6 SMITH+NEPHEW
                        TABLE 238 SMITH+NEPHEW: COMPANY OVERVIEW
                        FIGURE 39 SMITH+NEPHEW: COMPANY SNAPSHOT (2022)
             10.1.7 MEDIPOST CO., LTD.
                        TABLE 239 MEDIPOST CO., LTD.: COMPANY OVERVIEW
                        FIGURE 40 MEDIPOST CO., LTD.: COMPANY SNAPSHOT
             10.1.8 JCR PHARMACEUTICALS CO., LTD.
                        TABLE 240 JCR PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW
                        FIGURE 41 JCR PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT (2022)
             10.1.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED
                        TABLE 241 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
                        FIGURE 42 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
             10.1.10 CORESTEM, INC.
                        TABLE 242 CORESTEM, INC.: COMPANY OVERVIEW
                        FIGURE 43 CORESTEM, INC.: COMPANY SNAPSHOT (2021)
             10.1.11 VERICEL CORPORATION
                        TABLE 243 VERICEL CORPORATION: COMPANY OVERVIEW
                        FIGURE 44 VERICEL CORPORATION: COMPANY SNAPSHOT (2022)
             10.1.12 MIMEDX GROUP, INC.
                        TABLE 244 MIMEDX GROUP, INC.: COMPANY OVERVIEW
                        FIGURE 45 MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2022)
             10.1.13 ORGANOGENESIS INC.
                        TABLE 245 ORGANOGENESIS INC.: COMPANY OVERVIEW
                        FIGURE 46 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2022)
             10.1.14 MEDTRONIC
                        TABLE 246 MEDTRONIC: COMPANY OVERVIEW
                        FIGURE 47 MEDTRONIC: COMPANY SNAPSHOT (2022)
             10.1.15 BRISTOL-MYERS SQUIBB COMPANY
                        TABLE 247 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
                        FIGURE 48 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2022)
     10.2 OTHER PLAYERS 
             10.2.1 ORTHOCELL LTD.
                        TABLE 248 ORTHOCELL LTD.: COMPANY OVERVIEW
             10.2.2 MESOBLAST LTD.
                        TABLE 249 MESOBLAST LTD.: COMPANY OVERVIEW
             10.2.3 BIORESTORATIVE THERAPIES, INC.
                        TABLE 250 BIORESTORATIVE THERAPIES, INC.: COMPANY OVERVIEW
             10.2.4 PLURISTEM THERAPEUTICS INC.
                        TABLE 251 PLURISTEM THERAPEUTICS INC.: COMPANY OVERVIEW
             10.2.5 TEGOSCIENCE
                        TABLE 252 TEGOSCIENCE: COMPANY OVERVIEW
             10.2.6 ANTEROGEN.CO.,LTD.
                        TABLE 253 ANTEROGEN.CO.,LTD.: COMPANY OVERVIEW
             10.2.7 BLUEBIRD BIO, INC.
                        TABLE 254 BLUEBIRD BIO, INC.: COMPANY OVERVIEW
             10.2.8 STEMPEUTICS RESEARCH PVT. LTD.
                        TABLE 255 STEMPEUTICS RESEARCH PVT. LTD.: COMPANY OVERVIEW
             10.2.9 SIBIONO GENETECH CO. LTD.
                        TABLE 256 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW
             10.2.10 ASPECT BIOSYSTEMS
                        TABLE 257 ASPECT BIOSYSTEMS: COMPANY OVERVIEW
                        TABLE 258 ATHERSYS, INC.: COMPANY OVERVIEW
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
11 APPENDIX (Page No. - 297)
     11.1 DISCUSSION GUIDE 
     11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     11.3 CUSTOMIZATION OPTIONS 
     11.4 RELATED REPORTS 
     11.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the regenerative medicine market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the regenerative medicine market. The secondary sources used for this study include the Alliance for Regenerative Medicine (ARM), American Society for Cell Biology (ASCB), Centre for Commercialization of Regenerative Medicine (CCRM), European Society of Gene & Cell Therapy (ESGCT), National Center for Biotechnology Information (NCBI), Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, global product revenues, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global regenerative medicine market, which was validated through primary research.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Regenerative  medicine Market Size, and Share

Note: Tiers are defined based on a company’s total revenue. As of 2022, Tier 1 = >USD 1 Bn, Tier 2 = USD 500 Mn to USD 1 Bn, and Tier 3 <USD 500 Mn.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the regenerative medicine market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The major players in the industry and market have been identified through extensive primary and secondary research.
  • The product and company revenues generated from the regenerative medicine business of players operating in the market have been determined through secondary research and primary analysis.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Market Size Estimation Methodology-Bottom-up approach

Regenerative  medicine Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Top-down Approach-

Regenerative  medicine Market Size, and Share

Data Triangulation

After estimating the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Regenerative medicine refers to a branch of medical science that focuses on repairing, replacing, or regenerating damaged or diseased cells, tissues, or organs to restore normal function. This field employs various approaches, including stem cell therapy, gene therapy, tissue engineering, and other advanced techniques, to promote the body's natural healing processes.

Key Stakeholders

  • Regenerative medicine product manufacturing companies
  • Healthcare service providers (including hospitals & specialty clinics)
  • National and regional research boards and organizations
  • Research & development organizations
  • Clinical research organizations (CROs)
  • Research laboratories & academic institutes
  • Market research & consulting firms

The main objectives of this study are as follows:

  • To define, describe, and forecast the regenerative medicine market by product, therapeutic area, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall regenerative medicine market
  • To provide detailed information about global product revenues.
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five regions: North America (U.S., Canada), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), the Asia Pacific (China, Japan, India, Australia, South Korea, Rest of Asia Pacific), Latin America (Brazil, Rest of Latin America), the Middle East and Africa
  • To profile the key players and analyze their market shares and core competencies
  • To track and analyze competitive developments, such as product launches, pipeline products (Phase 3 Regenerative medicines clinical trials molecules), partnerships, agreements, collaborations, expansions, and strategic alliances
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report with additional efforts:

  • Product-Level Information

Country-wise Information:

  • Analysis for additional countries (up to five)

Company Information:

  • Detailed analysis and profiling of additional key market players across the globe
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 4419
Published ON
Jan, 2024
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Regenerative Medicine Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback